Clinical Trials for Pancreas Cancer

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable, MTAP‑deleted pancreatic ductal adenocarcinoma (measurable disease, adequate organs; no prior PRMT5/MAT2A inhibitors and, for the RAS combo, no prior MAPK/KRAS inhibitors) receive AMG 193, an oral MTA‑cooperative PRMT5 inhibitor exploiting MTAP synthetic lethality, combined with either gemcitabine/nab‑paclitaxel, modified FOLFIRINOX, or with RMC‑6236, an oral RAS(ON) tri‑complex inhibitor for RAS‑mutant cohorts. The study explores dose, safety, PK, and preliminary efficacy with expansion in defined PDAC cohorts.

ClinicalTrials.gov ID: NCT06360354

A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated locally advanced unresectable or metastatic exocrine pancreatic adenocarcinoma (ECOG 0–1) receive NALIRIFOX plus oral onvansertib, a selective PLK1 inhibitor given days 1–5 each 14-day cycle. Key exclusions include significant cardiac risk/QTc prolongation, uncontrolled infection, untreated brain mets, GI absorption issues, strong CYP3A4/CYP2C19 modulators, and clinically significant effusions.

ClinicalTrials.gov ID: NCT06736717

A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable PDAC after progression on a 5‑FU–based regimen (no prior gemcitabine/nab‑paclitaxel for advanced disease) receive emavusertib (CA‑4948), an oral IRAK4/FLT3 inhibitor targeting TLR/IL‑1R–NF‑κB signaling, combined with fixed-dose gemcitabine and nab‑paclitaxel. Prior gemcitabine in the adjuvant setting (>12 months) is allowed; ECOG 0–2 required; controlled HIV/HBV/HCV and treated, stable brain metastases permitted.

ClinicalTrials.gov ID: NCT05685602

A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic colorectal cancer (after 1–2 prior lines) or pancreatic ductal adenocarcinoma (after exactly 1 prior line), ECOG 0–1, receive monotherapy GSK5764227 (HS-20093), a B7-H3–targeted antibody-drug conjugate delivering a topoisomerase I inhibitor, at cohort-specific dose levels. Excludes active CNS mets, significant cardiovascular/hepatic/renal disease, prior topo‑I ADCs, and viral hepatitis; tumor tissue required for CRC and requested for PDAC.

ClinicalTrials.gov ID: NCT06885034

A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with locally advanced/metastatic, measurable KRAS-altered solid tumors (ECOG 0–1) not amenable to curative therapy, including expansion cohorts for colorectal cancer, pancreatic ductal adenocarcinoma, and other KRAS-altered tumors; prior KRAS G12C/G12D/pan-KRAS inhibitor exposure is not allowed. Treatment is oral single-agent JAB-23E73, a small-molecule pan-KRAS inhibitor designed to inhibit KRAS across ON and OFF states (with downstream MAPK suppression), with dose escalation/optimization followed by fixed-dose expansion.

ClinicalTrials.gov ID: NCT06973564

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with locally advanced/metastatic KRAS G12V–mutant solid tumors (ECOG 0–1, measurable disease) that have progressed on or are intolerant to standard therapies. Treatment is oral RMC-5127, a KRAS G12V–selective RAS(ON) inhibitor (cyclophilin A–enabled tri-complex), given alone or combined with oral daraxonrasib (pan-RAS(ON) inhibitor) or with cetuximab.

ClinicalTrials.gov ID: NCT07349537

A Phase 1b/2a, Multicenter, Open Label Study of the Safety, Efficacy and Pharmacokinetics of Narmafotinib in Combination With Modified FOLFIRINOX in Pancreatic Cancer Patients

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with newly diagnosed metastatic pancreatic ductal adenocarcinoma (confirmed within 6 weeks), measurable disease, ECOG 0–1, and eligible for modified FOLFIRINOX, with no prior systemic therapy for metastatic disease. Patients receive oral daily narmafotinib (AMP945), a selective focal adhesion kinase (FAK/PTK2) inhibitor intended to modulate the tumor microenvironment, combined with modified FOLFIRINOX on days 1 and 15 of 28-day cycles, with dose escalation/expansion to determine the optimal narmafotinib dose.

ClinicalTrials.gov ID: NCT07026279

Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adult patients with advanced solid tumors, including NSCLC, who have progressed after anti-PD-1/PD-L1 therapy to evaluate MEM-288, an oncolytic adenovirus with immunostimulatory properties, alone and in combination with the PD-1 inhibitor nivolumab.

ClinicalTrials.gov ID: NCT05076760

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: The trial involves adult patients with advanced solid tumors harboring specific RAS mutations, including KRAS G12, who have progressed after standard therapies, evaluating the safety and tolerability of RMC-6236, an oral selective inhibitor targeting active RAS(ON) with a novel 'tri-complex' mechanism. This investigational drug shows promising early efficacy, especially in KRAS G12X-related pancreatic and non-small cell lung cancers.

ClinicalTrials.gov ID: NCT05379985

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors harboring a KRAS G12C mutation, including both previously treated and some untreated NSCLC and CRC patients, to evaluate the oral KRAS G12C inhibitor LY3537982 (olomorasib) as monotherapy or in combination with pembrolizumab, cetuximab, pemetrexed, cisplatin, or carboplatin.

ClinicalTrials.gov ID: NCT04956640